FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082164706> ?p ?o ?g. }

• W3082164706 endingPage "1110" @default.
• W3082164706 startingPage "1106" @default.
• W3082164706 abstract "Inflammatory myofibroblastic tumour (IMT) is a rare malignancy with limited responses to corticosteroids and chemotherapy. About half of cases have activating rearrangements in the ALK gene which could be targeted with ALK inhibitors. A 40-year-old man presented with a large right lung mass and nodal, trapezius and cerebral metastases. Biopsy confirmed IMT with TPM4-ALK fusion. He was treated with prednisolone without clinical benefit. He received the Trk/ROS1/ALK inhibitor entrectinib in a clinical trial but his disease progressed in less than 3 months. Ifosfamide and etoposide in addition to radiotherapy to the brain and chest were administered. Transient improvement in the radiotherapy-treated areas was observed but his disease progressed shortly afterwards on all sites including the development of new adrenal metastasis. Compassionate use of the third-generation ALK inhibitor lorlatinib resulted in excellent partial response on all disease sites after 2 months, followed by a further 6 months of disease stabilisation. Repeat imaging showed slight increase in size of the cerebral metastasis but stable disease elsewhere, for which he was given stereotactic radiotherapy. His disease progressed 3 months later and lorlatinib was substituted with another ALK inhibitor brigatinib but he deteriorated and died shortly afterwards. Our patient tolerated lorlatinib well for 11 months with minimal toxicities, although he developed unilateral right-sided lung consolidation that was probably related to a combination of infection, radiotherapy and lorlatinib, which needed treatment with antibiotics and corticosteroids. This case demonstrates a role of lorlatinib in the treatment of TPM4-ALK-rearranged IMT despite failure of entrectinib." @default.
• W3082164706 created "2020-09-08" @default.
• W3082164706 creator A5029088635 @default.
• W3082164706 creator A5040009858 @default.
• W3082164706 creator A5047316860 @default.
• W3082164706 creator A5051681053 @default.
• W3082164706 creator A5059804195 @default.
• W3082164706 creator A5079147077 @default.
• W3082164706 creator A5091479854 @default.
• W3082164706 date "2020-08-27" @default.
• W3082164706 modified "2023-09-24" @default.
• W3082164706 title "Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib" @default.
• W3082164706 cites W1505421350 @default.
• W3082164706 cites W1998996807 @default.
• W3082164706 cites W2038586807 @default.
• W3082164706 cites W2068834404 @default.
• W3082164706 cites W2099530756 @default.
• W3082164706 cites W2104340741 @default.
• W3082164706 cites W2109770623 @default.
• W3082164706 cites W2155993108 @default.
• W3082164706 cites W2172208023 @default.
• W3082164706 cites W2205667543 @default.
• W3082164706 cites W2461870171 @default.
• W3082164706 cites W2482427906 @default.
• W3082164706 cites W2530267675 @default.
• W3082164706 cites W2581592505 @default.
• W3082164706 cites W2581996620 @default.
• W3082164706 cites W2607398004 @default.
• W3082164706 cites W2624310346 @default.
• W3082164706 cites W2734926149 @default.
• W3082164706 cites W2742652175 @default.
• W3082164706 cites W2749978328 @default.
• W3082164706 cites W2755495128 @default.
• W3082164706 cites W2797685139 @default.
• W3082164706 cites W2797695262 @default.
• W3082164706 cites W2883124357 @default.
• W3082164706 cites W2883764978 @default.
• W3082164706 cites W2894476389 @default.
• W3082164706 cites W2898009566 @default.
• W3082164706 cites W2899668190 @default.
• W3082164706 cites W2908885437 @default.
• W3082164706 cites W2947055368 @default.
• W3082164706 cites W2954565338 @default.
• W3082164706 cites W2972353415 @default.
• W3082164706 cites W2978074062 @default.
• W3082164706 doi "https://doi.org/10.1097/cad.0000000000000994" @default.
• W3082164706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32868646" @default.
• W3082164706 hasPublicationYear "2020" @default.
• W3082164706 type Work @default.
• W3082164706 sameAs 3082164706 @default.
• W3082164706 citedByCount "10" @default.
• W3082164706 countsByYear W30821647062021 @default.
• W3082164706 countsByYear W30821647062022 @default.
• W3082164706 countsByYear W30821647062023 @default.
• W3082164706 crossrefType "journal-article" @default.
• W3082164706 hasAuthorship W3082164706A5029088635 @default.
• W3082164706 hasAuthorship W3082164706A5040009858 @default.
• W3082164706 hasAuthorship W3082164706A5047316860 @default.
• W3082164706 hasAuthorship W3082164706A5051681053 @default.
• W3082164706 hasAuthorship W3082164706A5059804195 @default.
• W3082164706 hasAuthorship W3082164706A5079147077 @default.
• W3082164706 hasAuthorship W3082164706A5091479854 @default.
• W3082164706 hasConcept C117643217 @default.
• W3082164706 hasConcept C126322002 @default.
• W3082164706 hasConcept C143998085 @default.
• W3082164706 hasConcept C2776232967 @default.
• W3082164706 hasConcept C2776256026 @default.
• W3082164706 hasConcept C2776694085 @default.
• W3082164706 hasConcept C2776715498 @default.
• W3082164706 hasConcept C2778119113 @default.
• W3082164706 hasConcept C2778347629 @default.
• W3082164706 hasConcept C2779422266 @default.
• W3082164706 hasConcept C509974204 @default.
• W3082164706 hasConcept C71924100 @default.
• W3082164706 hasConcept C90924648 @default.
• W3082164706 hasConceptScore W3082164706C117643217 @default.
• W3082164706 hasConceptScore W3082164706C126322002 @default.
• W3082164706 hasConceptScore W3082164706C143998085 @default.
• W3082164706 hasConceptScore W3082164706C2776232967 @default.
• W3082164706 hasConceptScore W3082164706C2776256026 @default.
• W3082164706 hasConceptScore W3082164706C2776694085 @default.
• W3082164706 hasConceptScore W3082164706C2776715498 @default.
• W3082164706 hasConceptScore W3082164706C2778119113 @default.
• W3082164706 hasConceptScore W3082164706C2778347629 @default.
• W3082164706 hasConceptScore W3082164706C2779422266 @default.
• W3082164706 hasConceptScore W3082164706C509974204 @default.
• W3082164706 hasConceptScore W3082164706C71924100 @default.
• W3082164706 hasConceptScore W3082164706C90924648 @default.
• W3082164706 hasIssue "10" @default.
• W3082164706 hasLocation W30821647061 @default.
• W3082164706 hasOpenAccess W3082164706 @default.
• W3082164706 hasPrimaryLocation W30821647061 @default.
• W3082164706 hasRelatedWork W2516942920 @default.
• W3082164706 hasRelatedWork W2782109468 @default.
• W3082164706 hasRelatedWork W2795514639 @default.
• W3082164706 hasRelatedWork W2811223828 @default.
• W3082164706 hasRelatedWork W2968802677 @default.
• W3082164706 hasRelatedWork W2982087753 @default.

• next